Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-17-039234
Filing Date
2017-06-12
Accepted
2017-06-12 17:26:24
Documents
1
Period of Report
2017-06-08

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 5699
  Complete submission text file 0001209191-17-039234.txt   7127
Mailing Address C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Business Address
Fust Matthew K (Reporting) CIK: 0001397266 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36548 | Film No.: 17907432

Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Issuer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)